Concall AI

GlaxoSmithKline Pharmaceuticals Limited — Q4 FY25 earnings call

Call held 13 May 2025

Management summary

GlaxoSmithKline Pharmaceuticals reported a strong Q4 and full year FY25, with full year revenue growing 9% to INR 3723 crores and EBITDA up 30% to INR 1169 crores, driven by volume growth and margin expansion. The company successfully launched Shingrix, achieving 10,000 doses in March, and is preparing for oncology launches (Jemperli and Zejula). Despite a soft quarter for antibiotics and stunted growth in acute segments, the specialty and derms portfolios showed robust double-digit growth, supported by an enhanced digital strategy reaching over 400,000 HCPs.

Highlights

Full year revenue of INR 3723 crores, up 9% YoY.
Full year EBITDA of INR 1169 crores, up 30% YoY, with margins expanding from 26% to 31% YoY.
Full year PAT grew 32% and EPS grew 32%.
Q4 revenue grew 6%, Q4 EBITDA grew 30%, and Q4 PAT grew 36%.
Specialty segment grew 35% for the full year, and pediatric vaccines grew 12%.
Shingrix sales reached 10,000 doses in March 2025, with almost 20,000 doses in Q4.
Oncology products Jemperli and Zejula received marketing authorization and are set for launch in the coming months.
Company maintains a zero-debt status with INR 2,500 crores cash.
Derms business grew in double digits for the quarter and is the number one player in the segment.
Digital strategy led to over 400,000 unique HCP touchpoints, increasing reach by over 40%.

Concerns

External landscape did not evolve as expected in Q4, leading to stunted growth in acute segments of the Indian pharmaceutical market.
Anti-infectives portfolio experienced suppressed external growth of just about 3%.
Antibiotics had a soft quarter.
The company does not expect a significant upward change in the sustainable full-year margin of 31.4%.

Key financials

2 periods

Headline

Revenue (Full Year)
₹3,723 Cr
YoY +9%
EBITDA (Full Year)
₹1,169 Cr
YoY +30%
EBITDA Margin (Full Year)
31%
PAT Growth (Full Year)
—
YoY +32%
EPS Growth (Full Year)
—
YoY +32%

Q4

Revenue Growth
—
YoY +6%
EBITDA Growth
—
YoY +30%
PAT Growth
—
YoY +36%

What they filed

Q1 FY27: revenue up 16.5%, net profit up 15.6% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	1,011	949	974	805	980 −3%	1,041 +10%	995 +2%	938 +17%
Expenses	689	658	641	554	644	670	644	643
EBITDA	322	292	333	251	336 +4%	371 +27%	351 +5%	296 +18%
Margin	32%	31%	34%	31%	34%	36%	35%	31%
Other income	39	35	41	44	36	50	36	44
Interest	0	0	1	0	1	1	1	1
Depreciation	17	19	15	16	17	20	13	16
Profit before tax	344	308	359	279	354 +3%	400 +30%	373 +4%	322 +15%
Tax rate	27%	25%	27%	27%	27%	26%	26%	26%
Net profit	252	230	263	205	257 +2%	296 +29%	278 +6%	237 +16%
EPS	14.91	13.57	15.52	12.10	15.20	17.45	16.40	14.00

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

General Medicine (Full Year)
8% Volume Growth
Specialty Segment (Full Year)
35% Growth
Pediatric Vaccines (Full Year)
12% Growth
Pediatric Vaccines (Q4)
10% Growth
Anti-infectives (Q4)
3% External Growth
Derms Business (Q4)
— Growth

Capital allocation

high confidence

Debt Debt disclosed

We are a zero debt company and EPS growth of 32 percentage.
Dividend ₹42/share (final)

And you would have also noticed the Board has declared a final dividend of 42 per share. This is in addition to the interim dividend, which we had declared in the last quarter.
Liquidity Cash ₹2,500 Cr

We are sitting at a balance sheet date estimated close to INR 2,500 crores cash, very healthy balance sheet.

Guidance & targets

Profitability

EBITDA Margin (Full Year) Profitability · FY26 · High confidence 31.4%

for guidance, you might have to take the full year margin, which is a bit of margin of 31.4. This is what we are tracking as a sustainable margin. Now, you might have noticed the margin profile has gone up significantly, a lot of low hanging fruit. So, lots of changes we have made and we are at a perhaps at a stabilization stage. So, at this stage, you should not expect a big change in the margin profile upwards.

— Juby Chandy

Revenue

Revenue Growth Revenue · FY26 · High confidence above 8-9% (double digit)

Yes, absolutely. Our aspiration continues to hold. And that's something...So, if you've seen the IQVIA prognosis, the market is supposed to grow anywhere between 8% to 9%. And that's why you said we want to ensure that we deliver above market growth. So, the answer is yes.

— Bhushan Akshikar

Product Launch

Oncology Product Launches Product Launch · coming months / next month · High confidence Jemperli and Zejula

we have the marketing authorization for two of our global assets; Dostarlimab which is the brand - the trademark is Jemperli and Niraparib, which is Zejula, respectively, in gynecological malignancy. So, those are the first two ones, which will go off the block in terms of a long sequence in this coming financial year.

— Bhushan Akshikar
Drug Launch Lag Product Launch · Medium confidence reduced

I think the whole idea is to get the drug lag, the launch lag reduced. And that's the whole intent of having almost 19 global clinical trials happening in India as we speak, in the areas of oncology, in the areas of hepatology.

— Bhushan Akshikar
RSV Vaccine Trials Product Launch · High confidence ongoing in India

Moving forward, we have trials ongoing even in India for our RSV, respiratory syncytial virus vaccine, which will be the next adult vaccine.

— Bhushan Akshikar

Strategy

Growth Driver Strategy · High confidence volume-led

I think our strategy will still continue to be driven largely by volumes because that really is the best metric to tell you the health of the business, because that's the closest unit to your prescription generation that you're doing as a company.

— Bhushan Akshikar

What to watch in Q1 FY26

Progress of oncology launches (Jemperli, Zejula)

Next quarter / Coming months

Current Marketing authorization received, set to launch in coming months.

Target Initial launch traction, patient reach, early revenue contribution.

Why it matters

These are new growth drivers and represent the company's entry into the high-growth oncology segment.

we have the marketing authorization for two of our global assets; Dostarlimab which is the brand - the trademark is Jemperli and Niraparib, which is Zejula, respectively, in gynecological malignancy. So, those are the first two ones, which will go off the block in terms of a long sequence in this coming financial year.

Risks & concerns

Stunted growth in acute segments of the Indian pharmaceutical market
medium

The external landscape did not evolve as expected, leading to stunted growth, especially around acute segments of the Indian pharmaceutical market.

Management acknowledged
Suppressed external growth in the anti-infectives portfolio
medium

The anti-infectives portfolio experienced suppressed external growth of just about 3%.

Management acknowledged
Changing regulations and government push for generic medicines
medium

Hearings are ongoing in the Supreme Court regarding generic medicine promotion, which the company is monitoring.

Analyst acknowledged

Q&A highlights

6 direct

Margin sustainability and future expansion Direct

for guidance, you might have to take the full year margin, which is a bit of margin of 31.4. This is what we are tracking as a sustainable margin. Now, you might have noticed the margin profile has gone up significantly, a lot of low hanging fruit. So, lots of changes we have made and we are at a perhaps at a stabilization stage. So, at this stage, you should not expect a big change in the margin profile upwards.

Clarifies that the 31.4% full-year EBITDA margin is considered sustainable and further significant expansion is not expected, setting investor expectations.

Asked by Pritesh Chheda

New product launches (Oncology & Respiratory) Direct

we have the marketing authorization for two of our global assets; Dostarlimab which is the brand - the trademark is Jemperli and Niraparib, which is Zejula, respectively, in gynecological malignancy. So, those are the first two ones, which will go off the block in terms of a long sequence in this coming financial year.

Provides specific names of upcoming oncology launches (Jemperli, Zejula) and their therapeutic areas, confirming the company's entry into new growth segments.

Asked by Pritesh Chheda

5-year vision for the company Direct

our ambition will be to continue to bring energy because many of these trust marks that I talked of will remain relevant in the Indian setting. But how do you really accelerate the launch of our innovative assets and continue to be the frame of reference of everything around innovation in this country, which we've done for the last 100, 101 years now? That will be the way I will see it.

Outlines the long-term strategic focus on leveraging existing trusted brands while accelerating the launch of innovative assets, emphasizing innovation and shareholder returns.

Asked by Viraj Mithani

Discrepancy between IQVIA data and reported growth Partial

if you look at some of our key brands, the reflection is very, very similar. So, if you look at the top assets, our top key brands, big size brands, the reflection as you would see in the external syndicated research data, whether it is IQVIA or any other is very similar. I think where we have a sizable non-promoted portfolio which operates. ... Plus, the vaccine market is usually under-reported if you see what we report in vaccines because that doesn't go through the normal channels of pharmacies and medical stores and general distributors.

Addresses a common analyst concern about data discrepancies, attributing it to the company's non-promoted portfolio and the under-reporting nature of the vaccine market in syndicated data.

Asked by Deepak Malik

Doctor coverage and digital strategy impact Direct

although our absolute face-to-face coverage had gone down, because we had optimized our selling field force on the ground but we had dialed up a significant Omni-channel digital strategy. ... today we cover almost 2,75,000 distinct unique healthcare practitioners in the country. ... our reach has actually gone up by more than 40% on top of what we had. ... the 4 lakh plus touch points that we talk of, our reach and coverage has in fact increased over the last couple of years.

Details the success of the omni-channel digital strategy in expanding HCP reach to 275,000 unique practitioners and over 400,000 touchpoints, despite optimizing the field force.

Asked by Nikhil Upadhyay

Shingrix accessibility and market development Direct

I think it's a great opportunity to do some market shaping because as you can imagine, when you create a new category, it is I always say it's not a 100-meter sprint. It's an endurance sport where every quarter, every year you're learning, you're creating something different. ... we started touching 10,000 doses on a monthly basis. At a certain point, it doesn't follow a linear curve. It follows a different pattern.

Explains the long-term market shaping strategy for Shingrix, highlighting its non-linear growth trajectory and the focus on building an adult vaccination ecosystem rather than just sales.

Asked by Mahesh Vyas

Impact of changing regulations and generic medicine push Direct

hearings going on in the Supreme Court based on a case that was filed by an association. So we have to watch this space. ... Eventually, when a healthcare practitioner prescribes a medicine, he or she is prescribing it because of the evidence, body of evidence, the trust that the healthcare practitioner has. ... Uniform Code of Pharmaceutical Marketing Practices is already in place, which serves as a great guardrail for pharmaceutical companies to operate in.

Acknowledges the ongoing regulatory discussions regarding generic medicine promotion but emphasizes the importance of evidence-based prescribing and the existing UCPMP as a safeguard.

Asked by Swathi

2 min read 7 chapters

Detailed narrative

Strong Full Year FY25 Performance Driven by Volume and Margin Expansion

GlaxoSmithKline Pharmaceuticals reported a robust full year FY25, with revenue reaching INR 3723 crores, marking a 9% year-on-year growth. EBITDA surged by 30% to INR 1169 crores, and EBITDA margins expanded significantly from 26% in the previous year to 31%. This performance was primarily volume-led, with general medicines volume growing 8% and specialty segment revenue increasing by 35%.

Q4 FY25 Performance Amidst Market Challenges

For Q4 FY25, the company recorded a 6% revenue growth, a 30% increase in EBITDA, and a 36% rise in PAT. This was achieved despite a 'soft quarter' for antibiotics and 'stunted growth' in the acute segments of the Indian pharmaceutical market, where the anti-infectives portfolio saw suppressed external growth of just about 3%. Pediatric vaccines, however, maintained strong momentum with 10% growth in the quarter.

New Growth Platforms: Oncology and Respiratory

The company is actively building new growth platforms, particularly in oncology and respiratory. Marketing authorization has been secured for two global oncology assets, Jemperli (for endometrial cancer) and Zejula (for ovarian cancer), with launches anticipated in the coming months. In the respiratory segment, Trelegy and Nucala currently contribute INR 120-130 crores in annual revenues, with Trelegy identified as a key growth driver.

Shingrix and Adult Vaccination Ecosystem

Shingrix, the shingles vaccine, demonstrated strong traction, with almost 20,000 doses administered in Q4 FY25, including 10,000 doses in March alone. The company is focused on 'market shaping' to build an adult vaccination ecosystem, targeting 10-12 million Indians over 50 years of age who are eligible for prevention. Additionally, trials are ongoing in India for an RSV vaccine, which is expected to be the next adult vaccine.

Digital Transformation and Enhanced HCP Reach

GlaxoSmithKline Pharmaceuticals has significantly advanced its digital strategy, leading to a substantial increase in healthcare practitioner (HCP) engagement. Through its omni-channel and digital initiatives, the company now reaches approximately 275,000 distinct unique HCPs, with over 400,000 unique HCP touchpoints. This digital transformation has increased the company's reach by over 40% compared to previous periods, complementing its optimized field force.

Sustainable Margins and Volume-Led Strategy

The company's full-year EBITDA margin of 31.4% is considered sustainable, with management not expecting significant upward changes. The strategy remains largely volume-led, especially given that over half of the general medicines portfolio is under price control. While price increases are taken in the 60% non-NLEM portfolio where competitive, the focus is on driving volumes and maintaining market share.

Manufacturing and Regulatory Landscape

GlaxoSmithKline Pharmaceuticals operates its own manufacturing site in Nashik, which contributes over one-third of its top-line revenues for general medicines, and partners with 20 CMOs for the remaining 99% of its locally manufactured portfolio. The company is actively involved in 19 global clinical trials in India across oncology and hepatology, aiming to reduce drug launch lag. Management is monitoring ongoing Supreme Court hearings regarding generic medicine promotion, emphasizing evidence-based prescribing and the Uniform Code of Pharmaceutical Marketing Practices.

This is an AI-generated summary of a publicly available earnings call transcript.

View original transcript